Find recruiting clinical trials for UC in the UK — from first-line 5-ASAs to advanced biologic and small-molecule therapies. See where trials fit into your treatment pathway.
Free to use · Live data from ClinicalTrials.gov · Updated daily
See where clinical trials fit into your treatment journey
First-line treatment for mild to moderate ulcerative colitis
Standard: Mesalazine (oral and/or rectal), sulfasalazine, or olsalazine
When 5-ASAs alone aren't enough to control inflammation
Standard: Azathioprine, 6-Mercaptopurine, Methotrexate, or corticosteroids
For moderate-to-severe UC unresponsive to conventional therapy
Standard: Infliximab, Adalimumab, Golimumab, Vedolizumab, or Ustekinumab
After biologic failure — next-generation oral therapies
Standard: Tofacitinib, Upadacitinib, Ozanimod, or clinical trial
A chronic inflammatory bowel disease causing inflammation and ulcers in the colon and rectum. Affects about 120,000 people in the UK. Symptoms include bloody diarrhoea, abdominal pain, and fatigue.
Up to 40% of UC patients don't maintain remission with current treatments. Clinical trials offer access to new biologics, JAK inhibitors, and novel anti-inflammatory approaches before they're widely available.
Some patients develop acute severe flares requiring hospital treatment (IV steroids, ciclosporin, or infliximab rescue). Trials specifically targeting acute severe colitis are particularly important.
Loading trials from ClinicalTrials.gov...